Cargando…
Effectiveness of the second COVID-19 booster against Omicron: a large-scale cohort study in Chile
In light of the ongoing COVID-19 pandemic and the emergence of new SARS-CoV-2 variants, understanding the effectiveness of various booster vaccination regimens is pivotal. In Chile, using a prospective national cohort of 3.75 million individuals aged 20 or older, we evaluate the effectiveness agains...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603055/ https://www.ncbi.nlm.nih.gov/pubmed/37884492 http://dx.doi.org/10.1038/s41467-023-41942-y |
_version_ | 1785126519390076928 |
---|---|
author | Jara, Alejandro Cuadrado, Cristobal Undurraga, Eduardo A. García, Christian Nájera, Manuel Bertoglia, María Paz Vergara, Verónica Fernández, Jorge García-Escorza, Heriberto Araos, Rafael |
author_facet | Jara, Alejandro Cuadrado, Cristobal Undurraga, Eduardo A. García, Christian Nájera, Manuel Bertoglia, María Paz Vergara, Verónica Fernández, Jorge García-Escorza, Heriberto Araos, Rafael |
author_sort | Jara, Alejandro |
collection | PubMed |
description | In light of the ongoing COVID-19 pandemic and the emergence of new SARS-CoV-2 variants, understanding the effectiveness of various booster vaccination regimens is pivotal. In Chile, using a prospective national cohort of 3.75 million individuals aged 20 or older, we evaluate the effectiveness against COVID-19-related intensive care unit (ICU) admissions and death of mRNA-based second vaccine boosters for four different three-dose background regimes: BNT162b2 primary series followed by a homologous booster, and CoronaVac primary series followed by an mRNA booster, a homologous booster, and a ChAdOx-1 booster. We estimate the vaccine effectiveness weekly from February 14 to August 15, 2022, by determining hazard ratios of immunization over non-vaccination, accounting for relevant confounders. The overall adjusted effectiveness of a second mRNA booster shot is 88.2% (95%CI, 86.2–89.9) against ICU admissions and 90.5% (95%CI 89.4–91.4) against death. Vaccine effectiveness shows a mild decrease for all regimens and outcomes, probably linked to the introduction of BA.4 and BA.5 Omicron sub-lineages and the waning of immunity. Based on our findings, individuals might not need additional boosters for at least 6 months after receiving a second mRNA booster shot in this setting. |
format | Online Article Text |
id | pubmed-10603055 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-106030552023-10-28 Effectiveness of the second COVID-19 booster against Omicron: a large-scale cohort study in Chile Jara, Alejandro Cuadrado, Cristobal Undurraga, Eduardo A. García, Christian Nájera, Manuel Bertoglia, María Paz Vergara, Verónica Fernández, Jorge García-Escorza, Heriberto Araos, Rafael Nat Commun Article In light of the ongoing COVID-19 pandemic and the emergence of new SARS-CoV-2 variants, understanding the effectiveness of various booster vaccination regimens is pivotal. In Chile, using a prospective national cohort of 3.75 million individuals aged 20 or older, we evaluate the effectiveness against COVID-19-related intensive care unit (ICU) admissions and death of mRNA-based second vaccine boosters for four different three-dose background regimes: BNT162b2 primary series followed by a homologous booster, and CoronaVac primary series followed by an mRNA booster, a homologous booster, and a ChAdOx-1 booster. We estimate the vaccine effectiveness weekly from February 14 to August 15, 2022, by determining hazard ratios of immunization over non-vaccination, accounting for relevant confounders. The overall adjusted effectiveness of a second mRNA booster shot is 88.2% (95%CI, 86.2–89.9) against ICU admissions and 90.5% (95%CI 89.4–91.4) against death. Vaccine effectiveness shows a mild decrease for all regimens and outcomes, probably linked to the introduction of BA.4 and BA.5 Omicron sub-lineages and the waning of immunity. Based on our findings, individuals might not need additional boosters for at least 6 months after receiving a second mRNA booster shot in this setting. Nature Publishing Group UK 2023-10-27 /pmc/articles/PMC10603055/ /pubmed/37884492 http://dx.doi.org/10.1038/s41467-023-41942-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Jara, Alejandro Cuadrado, Cristobal Undurraga, Eduardo A. García, Christian Nájera, Manuel Bertoglia, María Paz Vergara, Verónica Fernández, Jorge García-Escorza, Heriberto Araos, Rafael Effectiveness of the second COVID-19 booster against Omicron: a large-scale cohort study in Chile |
title | Effectiveness of the second COVID-19 booster against Omicron: a large-scale cohort study in Chile |
title_full | Effectiveness of the second COVID-19 booster against Omicron: a large-scale cohort study in Chile |
title_fullStr | Effectiveness of the second COVID-19 booster against Omicron: a large-scale cohort study in Chile |
title_full_unstemmed | Effectiveness of the second COVID-19 booster against Omicron: a large-scale cohort study in Chile |
title_short | Effectiveness of the second COVID-19 booster against Omicron: a large-scale cohort study in Chile |
title_sort | effectiveness of the second covid-19 booster against omicron: a large-scale cohort study in chile |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603055/ https://www.ncbi.nlm.nih.gov/pubmed/37884492 http://dx.doi.org/10.1038/s41467-023-41942-y |
work_keys_str_mv | AT jaraalejandro effectivenessofthesecondcovid19boosteragainstomicronalargescalecohortstudyinchile AT cuadradocristobal effectivenessofthesecondcovid19boosteragainstomicronalargescalecohortstudyinchile AT undurragaeduardoa effectivenessofthesecondcovid19boosteragainstomicronalargescalecohortstudyinchile AT garciachristian effectivenessofthesecondcovid19boosteragainstomicronalargescalecohortstudyinchile AT najeramanuel effectivenessofthesecondcovid19boosteragainstomicronalargescalecohortstudyinchile AT bertogliamariapaz effectivenessofthesecondcovid19boosteragainstomicronalargescalecohortstudyinchile AT vergaraveronica effectivenessofthesecondcovid19boosteragainstomicronalargescalecohortstudyinchile AT fernandezjorge effectivenessofthesecondcovid19boosteragainstomicronalargescalecohortstudyinchile AT garciaescorzaheriberto effectivenessofthesecondcovid19boosteragainstomicronalargescalecohortstudyinchile AT araosrafael effectivenessofthesecondcovid19boosteragainstomicronalargescalecohortstudyinchile |